Asan Medical Center / 서울아산병원

Hospital


Location: Seoul, Korea, Republic of (KR) KR

ISNI: 0000000108422126

ROR: https://ror.org/03s5q0090

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article International consensus on the management of large (≥20 mm) colorectal laterally spreading tumors: World Endoscopy Organization Delphi study (2024) Djinbachian R, Rex DK, Chiu HM, Fukami N, Aihara H, Bastiaansen BA, Bechara R, et al. Journal article Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy (2021) Rugo H, Chow LWC, Cortes J, Fasching P, He XB, Hsu P, Huang CS, et al. Conference contribution Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial (2021) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study (2019) Feagan BG, Sandborn WJ, D'Haens GR, Panes J, Kaser A, Ferrante M, Louis E, et al. Conference contribution Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study (2018) Feagan BG, Panes J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, et al. Journal article Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study (2017) Feagan BG, Sandborn WJ, D'Haens G, Panes J, Kaser A, Ferrante M, Louis E, et al. Journal article Comparison between core-lab and site-read assessment of coronary CT angiography for detection of ischemia-causing lesions: a substudy of the NXT trial (2016) Marwan M, Gaur S, Leipsic J, Seneviratne S, Ito H, Mauri L, De Bruyne B, et al. Conference contribution